Jeanmarie Guenot Displays Scientific Expertise in the Development of Drugs to Combat Blood Cancer

 

Jeanmarie Guenot is a longtime professional in the biotechnology and pharmaceutical industries, with over 20 years of experience. Her working experience includes working in public and private firms, R & D, corporate and commercial development sector, venture capital, business development, and project, alliance management, and company building and rebuilding. Presently, she is the president and chief executive officer of Amphivena Therapeutics Incorporation. http://amphivena.com/amphivena_leaders/jeanmarie-guenot-ph-d/

 

Amphivena Therapeutics has its headquarters in San Francisco, California. The corporation develops progressive autoimmune therapy techniques to combat hematologic health conditions. In July 2013, the company received 14 million dollars from a funding sponsored by MPM Capital. Later that year, Amphivena signed an agreement with Janssen Biotech Incorporation to allow Janssen the right to acquire Amphivena in the case of an IND approval. In 2015, Amphivena and Janssen announced its achievement in selecting a medical candidate to help in further development of treatment of hematologic malignancies and the hidden tumor antigen. Amphivena then received an undisclosed payment, following an agreement with Johnson & Johnson Innovation.

 

According to her website, Jeanmarie Guenot graduated from the University of California with a PhD from the University of Pennsylvania and with an MBA from the Wharton school. She then trained for quantum mechanical and semi-empirical methodologies for molecular dynamics, and X-Ray, protein built prediction, drug design, and NMR refinement. Jeanmarie began her career at the Atlas Venture and was responsible for managing the venture capital investments and building the life science firms. She then moved on to specialize in science by working for Preclinical R & D as a chief scientist. Jeanmarie developed and discovered drugs to treat metabolic illnesses, autoimmune complications, inflammation, and oncology.

 

Dr. Guenot’s notable career achievements include building and operating the SKS Ocular that managed glaucoma therapeutics, ocular inflammation, and macular degeneration. She served Hoffmann-La Roche as a business advisor in their Basel and Shanghai offices before moving on to work for PDL BioPharma as the vice president of the firm and corporate development division.

Jeanmarie Guenot aims to eliminate blood cancers by developing innovative therapies that adapt to a patient’s immune system. The treatment is set to destroy tumor cells and their causative agents. The treatment will treat blood cancer by rebalancing the cellular environment needed for healthy blood creation, functioning, and circulation.